Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

February 20, 2021

Study Completion Date

February 20, 2021

Conditions
HyperphosphatemiaEnd Stage Renal DiseaseESRD
Interventions
DRUG

Ferric Citrate

Take the capsules with meals or immediately after meals.

DRUG

Sevelamer Carbonate

Take the tablets with meals.

Trial Locations (24)

Unknown

Baotou Central Hospital, Baotou

The General Hospital of the People's Liberation Army (PLAGH), Beijing

The Second Hospital of Jilin University, Changchun

Daping Hospital, Chongqing

The First Affiliated Hospital of Dalian Medical University, Dalian

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou

The First Affiliated Hospital/School Of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou

Jilin Guowen Hospital, Jilin

Jiujiang University Affiliated Hospital, Jiujiang

Meihekou Central Hospital, Meihekou

Jiangxi Provincial People's Hospital, Nanchang

The First Affiliated Hospital of Nanchang University, Nanchang

BenQ Medical Center, Nanjing

JiangSu Province Hospital (The First Affiliated Hospital of Nanjing Medical University), Nanjing

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

The Affiliated Hospital of Qingdao University, Qingdao

Changhai Hospital, Shanghai

Shengjing Hospital of China Medical University, Shenyang

Tonghua Central Hospital, Tonghua

Fifth Hospital in Wuhan, Wuhan

Renmin Hospital of Wuhan University, Wuhan

Zhongnan Hospital of Wuhan University, Wuhan

Henan Provincial People's Hospital, Zhengzhou

Affiliated Hospital of Zunyi Medical University, Zunyi

Sponsors
All Listed Sponsors
collaborator

Shandong Weigao Panion Pharmaceutical Co. Ltd.

UNKNOWN

lead

Panion & BF Biotech Inc.

INDUSTRY